[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003741
German
Original Title: Tezacaftor/Ivacaftor (Kombination mit Ivacaftor; zystische Fibrose, ab 12 Jahre, F508del-Mutation, homozygot)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a20-54.html
Year Published: 2020
URL for published report: https://www.iqwig.de/download/a20-54_tezacaftor-ivacaftor_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Cystic Fibrosis
  • Adult
  • Child
  • Adolescent
  • Drug Therapy, Combination
  • Quinolones
  • Chloride Channel Agonists
  • Indoles
  • Benzodioxoles
Keywords
  • Tezacaftor
  • Ivacaftor
  • Cystic Fibrosis
  • Child
  • Adolescent
  • Adult
  • Benefit Assessment
  • NCT02347657
  • NCT01807923
  • NCT01807949
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.